Rasonque Price Sets $480,000 Benchmark for New Cancer Pills

A breakthrough with a matching price

On August 26, the Food and Drug Administration approved daraxonrasib, a Revolution Medicines drug for metastatic pancreatic cancer that is sold under the brand name Rasonque.1 Pancreatic cancer has long been one of the worst diagnoses in oncology, and this approval is a real clinical advance for it. The other headline from the launch is the price. Revolution set a list price of $39,800 a month, which comes to roughly $478,000 for a full year of treatment.

Outlets have rounded that number in different ways. Bloomberg's report, carried by the Boston Herald, described it as more than $475,000 a year.17 Medical Daily worked it out as about $477,600 for twelve 30-day fills. The New York Times and KTLA used about $480,000 a year, or $663 per tablet.1216 The rounding doesn't matter much. Every version puts Rasonque among the most expensive cancer drugs ever launched.17

One small detail also varies between reports. The Times says the drug is taken as two pills a day. The Bloomberg-sourced report calls it a once-daily drug.17 Neither point changes the annual price the company has announced.

Why the clinical case is unusually strong

Much of the criticism of expensive cancer drugs has targeted medicines approved because they shrank tumors or slowed their growth, without proof that patients lived longer.1215 Rasonque is different. In its pivotal trial, patients with advanced pancreatic cancer who took the pill lived a median of 13.2 months, compared with 6.7 months for patients on chemotherapy.11 The Times reports that some trial patients have lived for years.

The drug is one of the first to broadly target RAS, a protein that drives tumor growth and is mutated in most pancreatic cancers.17 For years researchers could not build drugs that worked against all forms of RAS. Revolution got around the problem with a "molecular glue" approach.17 The FDA approved it for adults with metastatic disease who have already had chemotherapy or can't tolerate multidrug chemotherapy regimens.17

The science is broadly praised. Doctors at Dana-Farber and Memorial Sloan Kettering called the approval long-awaited and a major advance.17 Even a drug-pricing researcher concedes the point. Vanderbilt's Stacie Dusetzina said the drug delivers substantial benefit over existing treatment, which many high-priced cancer drugs don't, and that this makes it hard to judge whether the price is fair.11

A price that is ordinary now

The launch matters less as an outlier than as proof of how routine prices like this have become. The Institute for Clinical and Economic Review counted nine cancer drugs that launched above $400,000 a year in 2024 alone.11 Coverage of Rasonque lists other examples: one CAR-T therapy costs $600,000 for a single infusion, a competing CAR-T costs $550,000, a daily pill for gastrointestinal cancer lists at $520,000 a year, and a twice-daily leukemia pill costs $430,000 a year.12 Twenty years ago, a $100,000-a-year cancer drug was enough to draw sharp criticism.11

The trend reaches beyond oncology. A study reported by USA Today found that the typical annual price of a newly approved prescription drug is now above $250,000, and noted that cancer drugs often run much higher.7 A Senate HELP Committee minority report found that 23 drugs launched by companies with "most favored nation" pricing deals with the Trump administration averaged $353,000 at launch. Several cancer drugs on that list were priced well above that, including one at $1,035,000 and another at about $719,000.10

Prices on drugs already on the market keep rising too. The advocacy group Patients for Affordable Drugs counted 64 oncology drugs with price increases in the first weeks of 2026, and said 73% of January's increases outpaced inflation.4 The Senate minority report says Americans pay far more than patients abroad for the same drugs, citing Keytruda at about $210,000 in the U.S. versus $109,000 in Canada and $37,900 in Japan.10

The industry's argument and the critics' answer

Revolution says Rasonque's price reflects how different the drug is and how much it helps patients.11 The broader industry argument is that high prices pay for innovation that has turned some deadly cancers into chronic conditions and sometimes cured them. Smaller companies also say they need to recover heavy clinical-trial spending.1112 Revolution's finances support that last point at least in part. The company has lost about $4 billion since its founding in 2014, mostly because of $3.3 billion in research spending this decade.12

The same reporting also shows what investors expect to earn. Revolution's market value has risen to about $45 billion on hopes that Rasonque becomes a blockbuster.12 Analysts compiled by Bloomberg project more than $9 billion in sales by 2032.17 A Jefferies analyst called the price fair given the survival benefit and recent comparable launches.17

Critics don't accept that framing. Harvard's Aaron Kesselheim argues that drugmakers can charge whatever they think the market will bear, without any clear rationale.11 KTLA's consumer reporter made a similar point, noting that most other developed countries cap what drugmakers can charge for life-saving medicines.16 Even CVS, whose Caremark unit is reviewing Rasonque for coverage, called the drug a breakthrough while warning that prices this high can limit how many patients get access.1215

The weakest part of the research-cost argument is that it explains a company's need to recover losses, not the specific number it chose. Revolution's price matches recent comparable launches, which suggests it was set by benchmarking against other drugs rather than calculated from costs. The Jefferies comment that the price fits recent oncology comparables points the same way.17 In practice, each $400,000 launch becomes the reference point for the next one.

Who pays

The list price is only the starting point for negotiation. But discounts on cancer drugs are usually small compared with diabetes or autoimmune drugs, so the final price ends up close to the sticker price.11 Employers have named cancer their top medical-cost driver for five years running, according to the Business Group on Health.11

Experts expect most insurers to cover Rasonque because the evidence is strong and there are few alternatives. They also expect plans to limit coverage strictly to the patients the FDA approved it for, using prior authorization. That could keep out many patients who want the drug and lead to disputes over who qualifies.11 Revolution says it will give patients a few weeks of free pills while insurance delays are resolved. It will also provide the drug free to qualifying uninsured and underinsured patients.11 Before approval, more than 2,000 patients received the drug through an expanded-access program.11

For Medicare patients, who make up a large share of pancreatic cancer cases, the Inflation Reduction Act changes the math considerably. Cancer drugs are a protected class, so Medicare drug plans should be required to cover Rasonque. The law also caps annual out-of-pocket drug costs at $2,100 this year, rising to $2,400 in 2027.11 Dusetzina estimated that without the cap, many patients would have owed more than $25,000 a year.11 Commercially insured patients with high deductibles get less protection, and some will face large bills when deductibles reset in January.11

The FDA angle

The approval itself came quickly. Medical Daily reports that the FDA cleared Rasonque about six and a half months ahead of its review deadline under a pilot program meant to speed treatments tied to national health priorities. That program, the Commissioner's National Priority Voucher, has been criticized by Senate Democrats. Their minority report questions how the vouchers are awarded and notes that most products approved under the program so far come from companies with pricing deals with the administration.10

Rasonque appears to be the kind of drug a fast-track program is meant for: a first-of-its-kind treatment with a large survival benefit in a disease with few options. Still, its launch shows the gap in current policy. The FDA can now approve a drug months early, but nothing in the approval process addresses what the drug will cost. The cancer drugs Medicare has negotiated so far are older products, and Patients for Affordable Drugs says a proposed change to the timeline for small-molecule drugs would have left all the cancer drugs in the first three negotiation rounds ineligible.47

The bottom line

As a medicine, Rasonque is about as strong a case as a premium-priced cancer drug can make. That is why its price is revealing. If a drug that roughly doubles survival in pancreatic cancer comes in near $480,000 a year, and drugs with weaker evidence already cost about the same, then price is barely tracking how much a drug helps patients. The Medicare out-of-pocket cap protects older patients. Employers, commercially insured patients and taxpayers still pay close to full price, and nothing in current policy is likely to make the next launch any cheaper.